Dr. Lal PathLabs Reports Strong Q1 FY27 Results with Revenue Up 19.1% and Focus on Strategic Acquisitions
Dr. Lal PathLabs Limited has announced its un-audited financial results for the quarter ending June 30, 2026, reporting consolidated revenue of Rs 798 Crore, reflecting a significant growth rate in the diagnostic and healthcare service provider sector.The company reported strong operational performance across key metrics. Consolidated EBITDA increased by 28.7%, achieving a margin of 31.0% in Q1 FY27. Profit After Tax (PAT) stood at Rs 170 Crore, corresponding to a PAT margin of 21.4%.
In addition to the financial results, Dr. Lal PathLabs Limited announced an interim dividend equivalent to 50%, or Rs 5 per share. As of June 30, 2026, the company recorded Cash and Cash equivalents amounting to Rs 1,693 Crore.
Strategic Moves and Acquisitions
The company expanded its international footprint through strategic acquisitions during this period. Dr. Lal PathLabs acquired an 80% equity stake in Sunshine Healthcare Limited, a diagnostic business operating in Ghana, for a consideration not exceeding GHS 45.6 million. Additionally, the company invested in Neuome Technologies Private Limited by acquiring a 30% equity stake, focusing on innovative solutions in sample preservation and biobanking, for an amount not exceeding Rs 3.5 Cr.Consolidated Financial Performance Overview
The consolidated financial figures highlight robust growth compared to Q1 FY26. The following table details the key financial performance indicators:| Particulars | Q1 FY27 (Rs Cr) | Q1 FY26 (Rs Cr) | Growth Percentage |
|---|---|---|---|
| Revenue | 798 | 670 | 19.1% |
| EBITDA | 247 | 192 | 28.7% |
| Margins (EBITDA) | 31.0% | 28.7% | |
| PAT | 170 | 134 | 27.2% |
| Margins (PAT) | 21.4% | 20.0% | |
| EPS | 10.1 | 7.9 | 27.8% |
Further details of the consolidated financial overview are provided in the table below:
| Particulars | Q1 FY27 (Rs Cr) | Q1 FY26 (Rs Cr) | Growth Percentage |
|---|---|---|---|
| Revenue | 798 | 670 | 19.1% |
| Material consumed | 152 | 129 | - |
| Employee benefit Expenses | 133 | 124 | - |
| Fees to collection centres | 116 | 96 | - |
| Other Expenses | 150 | 129 | - |
| EBITDA | 247 | 192 | 28.7% |
| Margins (EBITDA) | 31.0% | 28.7% | - |
| Other Income | 32 | 28 | - |
| Depreciation Cost | 44 | 35 | - |
| Finance Cost | 6 | 5 | - |
| PBT | 229 | 181 | 26.3% |
| Margins (PBT) | 28.7% | 27.0% | - |
| Income Tax | 58 | 47 | - |
| PAT | 170 | 134 | 27.2% |
| Margins (PAT) | 21.4% | 20.0% | - |
| EPS | 10.1 | 7.9 | 27.8% |
Operational Scale
Dr. Lal PathLabs Limited operates as a comprehensive diagnostic service provider across India, offering patients and healthcare providers a broad range of diagnostic tests. As of March 31, 2026, the company maintained an extensive network comprising 312 clinical laboratories (including National Reference Lab at Delhi and Regional Reference Labs in Kolkata, Bangalore, and Mumbai), 7,727 Patient Service Centers (PSCs), and 13,935 Pick-up Points (PUPs). The customer base includes individual patients, hospitals, other healthcare providers, and corporate customers.LALPATHLAB Stock Price Movement
Shares of Dr. Lal Path Labs Ltd. are edging higher in live trading at ₹1711.8 as of 2:35 PM today, rising by 1.46% (₹24.70) from its previous close. The stock maintains significant momentum, with nearly 658,703 shares traded in the market thus far.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.